1. Home
  2. SILO vs GXAI Comparison

SILO vs GXAI Comparison

Compare SILO & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • GXAI
  • Stock Information
  • Founded
  • SILO 2010
  • GXAI 2021
  • Country
  • SILO United States
  • GXAI United States
  • Employees
  • SILO N/A
  • GXAI N/A
  • Industry
  • SILO Apparel
  • GXAI
  • Sector
  • SILO Consumer Discretionary
  • GXAI
  • Exchange
  • SILO Nasdaq
  • GXAI Nasdaq
  • Market Cap
  • SILO 4.5M
  • GXAI 9.7M
  • IPO Year
  • SILO N/A
  • GXAI 2023
  • Fundamental
  • Price
  • SILO $0.59
  • GXAI $1.26
  • Analyst Decision
  • SILO
  • GXAI
  • Analyst Count
  • SILO 0
  • GXAI 0
  • Target Price
  • SILO N/A
  • GXAI N/A
  • AVG Volume (30 Days)
  • SILO 321.4K
  • GXAI 159.4K
  • Earning Date
  • SILO 08-12-2025
  • GXAI 08-12-2025
  • Dividend Yield
  • SILO N/A
  • GXAI N/A
  • EPS Growth
  • SILO N/A
  • GXAI N/A
  • EPS
  • SILO N/A
  • GXAI N/A
  • Revenue
  • SILO $72,102.00
  • GXAI $27,740.00
  • Revenue This Year
  • SILO $1.86
  • GXAI N/A
  • Revenue Next Year
  • SILO N/A
  • GXAI N/A
  • P/E Ratio
  • SILO N/A
  • GXAI N/A
  • Revenue Growth
  • SILO N/A
  • GXAI 9987.27
  • 52 Week Low
  • SILO $0.41
  • GXAI $1.00
  • 52 Week High
  • SILO $4.50
  • GXAI $7.50
  • Technical
  • Relative Strength Index (RSI)
  • SILO 44.04
  • GXAI 41.89
  • Support Level
  • SILO $0.60
  • GXAI $1.30
  • Resistance Level
  • SILO $0.64
  • GXAI $1.65
  • Average True Range (ATR)
  • SILO 0.04
  • GXAI 0.10
  • MACD
  • SILO 0.00
  • GXAI -0.02
  • Stochastic Oscillator
  • SILO 2.48
  • GXAI 4.77

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Share on Social Networks: